Radioligand therapy is currently approved for a small number of cancers, but it may have wide applications and could become an important pillar of treatment for many types of cancers and other diseases. The 2020 policy report Radioligand therapy: realising the potential of targeted cancer care identified six barriers that need to be addressed in order to realise the potential of radioligand therapy across Europe.
For more information about each of these barriers and policy recommendations, please read Radioligand therapy: realising the potential of targeted cancer care.